From the Editor

The Sarcoma Journal enters its second full year with renewed commitment and energy


 

We begin this second full year publishing The Sarcoma Journal—Official Journal of the Sarcoma Foundation of AmericaTMwith renewed energy and dedication to its founding principle of communicating authoritative and comprehensive scientific information on the diagnosis and treatment of sarcomas and sarcoma subtypes.

Despite advances in treatment and management options for our patients, the need still exists for more effective treatment strategies, new treatment paradigms, and improved understanding of disease biology. This journal, along with its online platform, plays an important role in the dissemination of reliable, peer-reviewed content to the sarcoma community and aims to bridge the gap between bench and bedside.

To this end, we have again recruited an outstanding advisory board, many of whom have long-standing affiliations with the Sarcoma Foundation of America. With their help, the editorial staff and I will continue to build the journal and make it the number one academic and practice resource for the sarcoma community.

We invite you and your colleagues to submit original research, review articles, case reports, opinion pieces, and meeting summaries for publication. In this way we will create the robust forum we all desire.

Recommended Reading

Adjuvant chemotherapy benefits high-risk sarcoma patients
MDedge Hematology and Oncology
Novel molecular assay: Promising results in bone and soft tissue tumor evaluation
MDedge Hematology and Oncology
Addressing the rarity and complexities of sarcomas
MDedge Hematology and Oncology
PARP inhibitor plus trabectedin shows promise for sarcoma
MDedge Hematology and Oncology
FDA lifts partial hold on tazemetostat trials
MDedge Hematology and Oncology
Predicting treatment response in leiomyosarcoma, liposarcoma
MDedge Hematology and Oncology
FDA approves larotrectinib for cancers with NTRK gene fusions
MDedge Hematology and Oncology
Reports from the annual meeting of The Connective Tissue Oncology Society held in Rome, November 14-17, 2018 Sarcoma of the Year: Intimal Sarcoma
MDedge Hematology and Oncology
Soft Tissue Sarcoma Chemotherapy
MDedge Hematology and Oncology
Sorafenib extends PFS for refractory desmoid tumors
MDedge Hematology and Oncology